TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01654549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.pylori eradication
Description: Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)
Study: NCT03768167

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Posterolateral corpectomy
Description: Investigators' goal in this study is to report clinical series of 26 patients in Sohag university hospital with dorsolumbar metastatic lesions from different primaries treated by single-stage posterolateral circumferential corpectomy with reconstruction by a pyramesh titanium cage and account the degree of improvement regarding the pain.
Study: NCT01587508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meloxicam/cyclobenzaprine hydrochloride
Description: two oral capsules a day during approximately 07 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meloxicam - Movatec®
Description: two oral tablet a day during approximately 07 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclobenzaprine - Miosan®
Description: two oral tablet a day during approximately 07 days
Study: NCT04910893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytokine Adsorption
Description: Cytokine adsorption therapy will be provided continuously for 72 hours by means of the CytoSorb® (CytoSorbents Corporation, Monmouth Junction, USA) column, run in series to a veno-venous continuous hemodialysis system, which will be exchanged every 24 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard intensive care of patients suffering septic shock
Study: NCT00361543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene hydrochloride
Description: 120 mg per capsule (1 tablet daily)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Capsules
Description: 1 tablet daily for 12 weeks
Study: NCT03382496

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT02010840

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation program
Study: NCT01638910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027)
Description: Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)
Study: NCT03159897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Comparator arm: cycle 1-2 (and eventually 3-6): 25 mg/m2 i.v. days 1,15. Experimental arm: Cycles 1 to 4: 35 mg/m2 i.v. days 1,11. Cycles 5 and 6: 25 mg/m2 i.v. days 1,11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Comparator arm: cycle 1-2 (and eventually 3-6): 25 mg/m2 i.v. days 1,15. Experimental arm: Cycles 1 to 4: 35 mg/m2 i.v. days 1,11. Cycles 5 and 6: 25 mg/m2 i.v. days 1,11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Bleomicina Comparator arm: cycle 1-2 (and eventually 3-6): 10,000 units/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 10,000 units/m2 i.v. days 1,11. Cycles 5 and 6: 10,000 units/m2 i.v. days 1,11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Bleomicina Comparator arm: cycle 1-2 (and eventually 3-6): 10,000 units/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 10,000 units/m2 i.v. days 1,11. Cycles 5 and 6: 10,000 units/m2 i.v. days 1,11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastina Comparator arm: cycle 1-2 (and eventually 3-6): 6 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 6 mg/m2 i.v. days 1,11. Cycles 5 and 6: 6 mg/m2 i.v. days 1,11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastina Comparator arm: cycle 1-2 (and eventually 3-6): 6 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 6 mg/m2 i.v. days 1,11. Cycles 5 and 6: 6 mg/m2 i.v. days 1,11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazina Comparator arm: cycle 1-2 (and eventually 3-6): 375 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 375 mg/m2 i.v. days 1,11. Cycles 5 and 6: 375 mg/m2 i.v. days 1,11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazina Comparator arm: cycle 1-2 (and eventually 3-6): 375 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 375 mg/m2 i.v. days 1,11. Cycles 5 and 6: 375 mg/m2 i.v. days 1,11.
Study: NCT04224155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enVista MX60EFH trifocal intraocular lenses (IOLs)
Description: enVista MX60EFH trifocal intraocular lenses (IOLs) implanted bilaterally

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enVista MX60E monofocal intraocular lenses (IOLs)
Description: enVista MX60E monofocal intraocular lenses (IOLs) implanted bilaterally
Study: NCT05610878

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured ASCs enrichment fat grafting
Description: Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs and grafted into recipient site with 1,00,000 cells/ml injected fat

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Curcumin-preconditioned ASCs enrichment fat grafting
Description: Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs preconditioned with curcumin and grafted into recipient site with 1,00,000 cells/ml injected fat

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fat grafting
Description: Patients will undergo conventional fat harvesting and grafting of fat into recipient site
Study: NCT02868788

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary fiber
Description: Fiber one supplement (32 grams of fiber) will be consumed with 910 Calorie HFHC meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFHC meal
Description: 910 Calorie HFHC meal

Intervention type: OTHER
Group type: OTHER
Intervention: HFHC meal
Description: 910 Calorie HFHC meal
Study: NCT04491136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI/ARB
Description: Oral ACE/ARB drug according to the investigator's discretion for the first 6 months in this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARNI
Description: Oral sacubitril/valsartan at the dosage of investigators discretion, whit a target dose of 200mg bid for the next 6 months of this study
Study: NCT02056873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous DBS
Description: The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~The DBS system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for DBS. At 6 months, the investigators will determine whether or not the subject is a candidate for responsive brain stimulation (RBS). Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. Subjects who do not qualify or do not participate will continue to receive this intervention for the duration of the study. These subjects will been seen every 6 months for evaluation as part of normal clinical care for DBS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Responsive Brain Stimulation (RBS Setting)
Description: The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~Six months post-surgery, the DBS system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for DBS.~Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention.
Study: NCT03829072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooking Education
Description: cooking Education and adapted physical activity on patients after allo stem cell transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adapted physical activity
Description: cooking Education and adapted physical activity on patients after allo stem cell transplantation
Study: NCT03329547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime test capsule
Description: SKF101804/cefixime test capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as a dark purple head and off white body locking type capsule with GSK' printed on cap and 400MG printed on body of capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime test capsule
Description: SKF101804/cefixime test capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as a dark purple head and off white body locking type capsule with GSK' printed on cap and 400MG printed on body of capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime reference capsule
Description: Cefixime reference capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as red/orange hard gelatin size 0 capsule with Cefspan 400 mg printed on body of capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime reference capsule
Description: Cefixime reference capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as red/orange hard gelatin size 0 capsule with Cefspan 400 mg printed on body of capsule.
Study: NCT03787719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Twice per week dialysis
Description: Twice-weekly 4 hour dialysis treatment
Study: NCT02878590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BONGO DEVICE
Description: A device to be used for the treatment of mild to moderate obstructive sleep apnea
Study: NCT05460351

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BRJ+Nitrate
Description: Participants in this group drank a 70 mL bottle of Beet It Sport drink with nitrate plus 15 grams of whey protein 3 days a week following a resistance exercise training program

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants in this group drank a 70 mL bottle of Beet It Sport drink without nitrate plus 15 grams of whey protein 3 days a week following a resistance exercise training program
Study: NCT03446027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: NMES device to be used for up to 3 hours daily in 30 minute sessions for 3 months.
Study: NCT02573181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: V114 contains 2 µg of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F, and 4 μg of serotype 6B; and 30 µg of CRM₁₉₇ and 125 µg of Aluminum Phosphate Adjuvant (APA) per 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Prevnar 13™ contains 2.2 μg of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and 4.4 μg of serotype 6B; and 34 μg of CRM₁₉₇ and 125 μg of aluminum per 0.5mL dose.
Study: NCT00485251

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hand-assisted laparoscopic right hemicolectomy
Description: using the lap disc that allows the insertion of single and into the abdomen for operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total laparoscopic right hemicolectomy
Description: using laparoscopic instruments for mobilization and dissection inside the abdomen

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hand-assisted right hemicolectomy
Description: hand-assisted right hemicolectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic right hemicolectomy
Description: using laparoscopic instruments for mobilization and dissection inside the abdomen
Study: NCT03681548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 1 patients will receive either reference or test product, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 1 patients will receive either reference or test product, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation
Study: NCT03401398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone, sodium succinate
Description: Patients randomized to the hydrocortisone treatment arm will receive an initial bolus of 2 mg/kg IV hydrocortisone, followed by 1 mg/kg (maximum 50 mg) of hydrocortisone dosed every six hours for a maximum of seven days or until all vasoactive infusions have been discontinued for at least 12 hours, whichever comes first. When the hydrocortisone course is completed, the medication will be discontinued.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients randomized to the placebo treatment arm will receive an equivalent volume of normal saline, with the identical dosing schedule to the intervention (hydrocortisone) arm.
Study: NCT00070499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01169337

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo observation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04297683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262
Description: Drug: ABBV-CLS-7162~Administration: Oral~Dose: Dose 1 or Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL343
Description: Drug: DNL343~Administration: Oral~Dose: Once per day
Study: NCT03737149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mymobility with Apple Watch
Description: The mymobility mobile application is a mobile software platform designed to facilitate remote episode of care management and asynchronous communication between the provider care team and their patient via provider-approved care plans and engagement communications. Current care pathways have been developed for: Total Hip Replacement, Total Knee Replacement and Partial Knee Replacement. Designed for the orthopedic population, mymobility also integrates wearable data from the Apple Watch into provider dashboards, providing enhanced understanding and monitoring of patients throughout the episode of care.
Study: NCT02904577

Intervention type: OTHER
Intervention: Any treatment, watch and wait policy included
Description: Patients registered in the study despite their planned treatment, watch and wait policy included. The planned treatment mentioned in the protocol is just the ideal approach proposed by investigators.The treatment can change depending on the evolution of the disease, without this affects the study's purposes.
Study: NCT03272373

Intervention type: DEVICE
Group type: OTHER
Intervention: NexGen TM Monoblock Tibia
Description: Primary cementless tibia total knee arthroplasty
Study: NCT04027491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The selected commercial games are aimed mostly to improve upper limb functions. The games will be randomly administered during each session. Each game will be played for approximately 10 minutes, with 5 minutes break between each game session.~The intervention treatment consists of 12 sessions in 4-week period.
Study: NCT03272373

Intervention type: DEVICE
Group type: OTHER
Intervention: NexGen TM Modular Tibia
Description: Primary cementless tibia total knee arthroplasty
Study: NCT03250975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide and Azithromycin
Description: Participant with acute laryngeal injury will be randomized at discharge to either a non-drug placebo control group or a medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control of budesonide and azithromycin
Description: placebos of the medications will be given for 14 days in patients randomized to the control group
Study: NCT02104310

Intervention type: DRUG
Intervention: Fluorine-18-L-dihydroxyphenylalanine
Description: 5 millicuries ± 10%; Intravenous injection; 1 time
Study: NCT01112488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Engagement Programme
Description: Patient's Diary, Ad Hoc medical support and Ad Hoc Clinical admission, Early post discharge Home visit
Study: NCT03991923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XVIVO heart preservation devices
Description: The intervention is to preserve hearts during transportation cold, cardioplegic and non-ischemic, with a high oncotic and hormone supplemented perfusate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ICSS
Description: Cold static preservation using standard preservation solution
Study: NCT04010760

Intervention type: DIAGNOSTIC_TEST
Intervention: Test of biomarkers for PE in EBC
Description: New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath condensate (EBC).~The EBC will be collected by use of the RTube(R) system which has been used in previous studies of EBC. As the patient breathes through a mouth piece, the exhaled breath is led through a cooling chamber where the vaporous part of the exhaled breath condenses.~We aim at collecting a total minimum of 3.0 mL EBC per study subject in order to have a sufficient amount of protein for the subsequent analysis. We aim at collecting exhaled breath condensate for 2\*15 minutes with the possibility to stop the collection after less than 15 minutes if the volume is sufficient.

Intervention type: DIAGNOSTIC_TEST
Intervention: Test of biomarkers for PE in EBC
Description: New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath condensate (EBC).~The EBC will be collected by use of the RTube(R) system which has been used in previous studies of EBC. As the patient breathes through a mouth piece, the exhaled breath is led through a cooling chamber where the vaporous part of the exhaled breath condenses.~We aim at collecting a total minimum of 3.0 mL EBC per study subject in order to have a sufficient amount of protein for the subsequent analysis. We aim at collecting exhaled breath condensate for 2\*15 minutes with the possibility to stop the collection after less than 15 minutes if the volume is sufficient.
Study: NCT03594448

Intervention type: PROCEDURE
Intervention: Specimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Intervention: Serial Liquid Biopsy
Description: Undergo serial liquid biopsy
Study: NCT03444064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PolyTregs
Description: Treatment group receive PolyTregs 6 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
Study: NCT03448354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC(paclitaxel 175mg/m2, 90min; open or closed technique) after IDS . IDS is recommended within 4 weeks after the 3rd NAC cycle. HIPEC procedure is allowed only in case of residual disease less than 5mm.
Study: NCT01052870

Intervention type: DRUG
Group type: OTHER
Intervention: Finasteride
Description: Effect of 1 mg finasteride on women with androgenetic alopecia depending on their AR gene polymorphism (androgen sensitivity)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: Effect of 1 mg finasteride on women with androgenetic alopecia depending on their AR gene polymorphism (androgen sensitivity)